Our systematic review found that GLP-1 RAs (such as exenatide, liraglutide, semaglutide, and the dual agonist tirzepatide) may significantly improve multiple facets of IIH: headaches, visual function, and induce substantial weight loss
Among patients with 2 prescription fills, the adjusted hazard ratios for the composite herpes outcome were directionally consistent with the primary analysis (Additional file 1: Table S16), indicating that prolonged GLP-1RA exposure may continue to confer an elevated risk
Weight of evidence: Overall evidence is Low-Moderate: multiple animal studies and a growing number of small clinical trials suggest benefits across gutbrain signaling, social and behavioral domains, gastrointestinal symptoms, and neurophysiological patterns, yet most human studies rely on caregiver-reported outcomes, lack biomarker integration, and seldom control for diet, comorbidities, or baseline microbiome composition
Joo JH, et al
Food and Drug Administration (FDA) approves Eli Lillys Mounjaro (tirzepatide) for treatment in adults with Type 2 diabetes
References to food supplements have not been evaluated by the EFSA (European Food Safety Authority) and are not intended to diagnose, treat, cure, or prevent any disease